Last reviewed · How we verify

Tavneos — Competitive Intelligence Brief

Tavneos (AVACOPAN) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement 5a Receptor Antagonist [EPC]. Area: Rare Disease.

marketed Complement 5a Receptor Antagonist [EPC] C5a anaphylatoxin chemotactic receptor 1 Rare Disease Small molecule Live · refreshed every 30 min

Target snapshot

Tavneos (AVACOPAN) — Chemocentryx. Tavneos blocks the action of a chemical called C5a, which is involved in the body's inflammatory response.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Tavneos TARGET AVACOPAN Chemocentryx marketed Complement 5a Receptor Antagonist [EPC] C5a anaphylatoxin chemotactic receptor 1 2021-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Complement 5a Receptor Antagonist [EPC] class)

  1. Chemocentryx · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tavneos — Competitive Intelligence Brief. https://druglandscape.com/ci/avacopan. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: